Metagenics, a practitioner-focused nutritional supplements company backed by Gryphon Investors, has acquired Symprove, a UK-based probiotic brand, from bd-capital as it looks to expand its presence in gut health and accelerate global growth. Financial terms were not disclosed.
Alongside the acquisition, Metagenics and Gryphon said they completed a strategic debt recapitalization intended to provide additional capital for continued organic investment and future M&A.
Symprove, known for a liquid, water-based probiotic formulation aimed at supporting the gut microbiome, will continue to operate under its existing leadership, with CEO Will Bowler remaining at the helm. Metagenics CEO Patrick Sly said Symprove’s science-based positioning and microbiome focus align with Metagenics’ core areas and product portfolio.
The transaction included a broad set of advisors on both sides. Greenhill & Co. International and Spayne Lindsay advised Gryphon, with Kirkland & Ellis serving as legal counsel and KPMG providing accounting and financial due diligence services. Jefferies, Stephenson Harwood, PwC, and OC&C advised bd-capital.
Metagenics, founded in 1983 and headquartered in Aliso Viejo, California, sells science-based supplements, medical foods, and lifestyle programs through healthcare practitioners and operates across North America, Europe, Asia, and Australia. Gryphon Investors is a middle-market private investment firm with more than $10 billion in assets under management and strategies spanning control equity and junior capital investments.
KEY QUOTES:
“We have never been more excited for the future of Metagenics. Symprove’s differentiated product is highly strategic for Metagenics’s portfolio of practitioner-recommended supplements. Through its global network of partnerships with healthcare practitioners, Metagenics will be able to grow patient engagement and improve patient results with Symprove’s technology in markets around the world. This acquisition is a significant inflection point for our partnership with Metagenics, and we are eager to pursue similar strategic acquisition opportunities.”
Ryan Fagan, Deal Partner, Consumer Group, Gryphon Investors
“We are delighted to welcome Symprove to Metagenics. Its science-based, unique probiotic formulation centers on the gut microbiome – a core area for Metagenics – and is a great fit for our family of supplements. We look forward to working with Will and his team to further develop products that we believe will support the health and wellness of millions of consumers globally.”
Patrick Sly, CEO, Metagenics
“After substantial growth during our partnership with bd-capital, becoming part of Metagenics is a great next step for Symprove as we look to scale and reach a wider market. Together, we will work toward becoming the world’s leading brand in gut health.”
Will Bowler, CEO, Symprove
